BRAND NAME:

Tuglif-S

GENERIC NAME:

Ertugliflozin + Sitagliptin HCl

THERAPEUTIC SEGMENT:

Antidiabetic

INDICATIONS:

Tuglif-S is a combination of ertugliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

BRIEF DESCRIPTION:

Ertugliflozin + Sitagliptin is an orally bioavailable, fixed-dose combination therapy for the management of type 2 diabetes mellitus (T2DM). Ertugliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, lowers blood glucose by inhibiting renal glucose reabsorption, promoting glycosuria, and providing additional benefits such as weight reduction and blood pressure control. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, leading to glucose-dependent insulin secretion and reduced glucagon levels, thereby improving postprandial glycemic control. This combination targets multiple pathways of glucose regulation, offering effective glycemic management with a low risk of hypoglycemia and potential cardiovascular benefits.

DOSAGE FORM:

Tablets

5mg+100mg

15mg+100mg